Contrasting Integra LifeSciences Holdings Corporation (IART) & Lombard Medical (EVAR)

Lombard Medical (NASDAQ: EVAR) and Integra LifeSciences Holdings Corporation (NASDAQ:IART) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Institutional and Insider Ownership

44.3% of Lombard Medical shares are held by institutional investors. Comparatively, 85.7% of Integra LifeSciences Holdings Corporation shares are held by institutional investors. 21.5% of Integra LifeSciences Holdings Corporation shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Lombard Medical and Integra LifeSciences Holdings Corporation’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
Lombard Medical	$12.17 million	1.10	-$24.22 million	($1.54)	-0.31
Integra LifeSciences Holdings Corporation	$1.05 billion	3.73	$240.98 million	$0.82	61.24

Integra LifeSciences Holdings Corporation has higher revenue and earnings than Lombard Medical. Lombard Medical is trading at a lower price-to-earnings ratio than Integra LifeSciences Holdings Corporation, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Lombard Medical has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Integra LifeSciences Holdings Corporation has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

Profitability

This table compares Lombard Medical and Integra LifeSciences Holdings Corporation’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lombard Medical	-255.03%	-124.24%	-41.26%
Integra LifeSciences Holdings Corporation	6.27%	16.79%	7.35%

Analyst Ratings

This is a summary of current ratings for Lombard Medical and Integra LifeSciences Holdings Corporation, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lombard Medical	0	2	0	0	2.00
Integra LifeSciences Holdings Corporation	0	2	8	0	2.80

Lombard Medical presently has a consensus target price of $1.00, indicating a potential upside of 108.94%. Integra LifeSciences Holdings Corporation has a consensus target price of $52.35, indicating a potential upside of 4.24%. Given Lombard Medical’s higher possible upside, equities research analysts clearly believe Lombard Medical is more favorable than Integra LifeSciences Holdings Corporation.

Summary

Integra LifeSciences Holdings Corporation beats Lombard Medical on 11 of the 13 factors compared between the two stocks.

About Lombard Medical

Lombard Medical, Inc. is a medical technology company. The Company specializes in developing, manufacturing, and marketing endovascular stent-grafts that address medical needs in the repair of aortic aneurysms. The Company’s Aorfix is an abdominal aortic aneurysm (AAA) stent-graft for the treatment of AAAs with angulation at the neck of the aneurysm of over 90 degrees. The Company supplies Aorfix pre-loaded into a delivery system, Aorflex, which is designed for accurate placement of Aorfix in the abdominal aorta. Once Aorfix is properly placed within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. It also offers IntelliFlex, which is a delivery system technology created for Aorfix AAA stent graft, and Altura Endovascular Stent Graft System that offers a simple and predictable solution to the treatment of standard AAA anatomies.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.